EML4-ALK fusions have also been identified in other cancer types such as metastatic colon cancer and breast cancer, suggesting the use of TKIs as part of the treatment plan to disrupt the kinase cascade in triggered oncogenic signaling. The gene discussed is ALK; the disease is cancer.